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Incretin-based therapies offer a new approach for the management of type 2 diabetes, with a mechanism of 
action distinct from any existing class of glucose-lowering agents.1 These drugs improve the body's ability to 
control blood glucose by increasing active concentrations of glucagon-like peptide-1 (GLP-1). Two approaches 
have been used to enhance the action of GLP-1. First, incretin mimetics (exenatide) or analogues (liraglutide) act 
as agonists at the GLP-1 receptor to mimic the effect of endogenous GLP-1, but are resistant to degradation by 
dipeptidyl peptidase-4 (DPP-4). Second, drugs that specifically inhibit DPP-4 (sitagliptin, vildagliptin, 
saxagliptin) are used to increase the half-life of endogenous GLP-1 that is secreted in response to food intake. 
Both approaches have proven efficacy for reducing the concentration of glycosylated haemoglobin (HbA1c), 
without inducing severe hypoglycaemic episodes or promoting weight gain.1 The drugs can be used alone or in 
combination with other oral glucose-lowering agents, such as metformin, sulphonylureas, andthiazolidinediones. 
Almost all published randomised trials of incretin therapies compared the new compound with a placebo or a 
reference glucose-lowering agent, but head-to-head comparisons between two incretin-based therapies are 
scarce. Onetrial compared 1.8 mg liraglutide once daily with 10 µg exenatide twice daily, and showed greater 
efficacy and better tolerance with liraglutide.2 2 mg exenatide (longacting release) once weekly was more 
effective and bettertolerated than 10 µg exenatide twice daily.3 No long-term comparisons of GLP-1 receptor 
agonists with DPP-4 inhibitors have been published, except in abstract form.4 Therefore evidence is lacking to 
clearly position GLP-1 receptor agonists versus DPP-4 inhibitors after failure to manage type 2 diabetes with 
metformin.5
Thus Richard Pratley and colleagues' 26-week, randomised, parallel-group, open-label trial,6 published in The 
Lancet today, is of great interest. Added to metformin, 1.2 mg and 1.8 mg liraglutide once daily significantly 
improved blood glucose control (change in HbA1c from baseline: -1.24%, 95% Cl -1.37 to -1.11 for 1.2 mg; -
1.50%, -1.63 to -1.37 for 1.8 mg) versus 100 mg sitagliptin once daily (-0.90%, -1.03 to -0.77; p<0.0001 for both 
comparisons). Furthermore, reductions in bodyweight were greater with 1.2 mg and 1.8 mg liraglutide (-2.86 kg, 
-3.39 to -2.32 for 1.2 mg; -3.38 kg, -3.91 to -2.84 for 1.8 mg) than with sitagliptin (-0.96 kg, -1.50 to -0.42; 
p<0.0001 for both comparisons). These results confirm previous reports of either liraglutide2,7 or sitagliptin8-10 in 
patients with type 2 diabetes that was not well controlled with diet and metformin. Further, similar findings were 
recorded with exenatide twice daily,3,11 exenatide (longacting release) once weekly,2-4 and DPP-4 inhibitors 
vildagliptin12 and saxagliptin13 (table). 
Findings from today's study show the superiority of 1.8 mg versus 1.2 mg liraglutide for reduction of HbA1c, 
butthis result has not been recorded in previous studies (table).7 Only the 1.8 mg dose of liraglutide was assessed 
in LEAD-6,2 in which liraglutide once daily was shown to be superior to 10 µg exenatide twice daily for 
reduction of HbA1c. Therefore 1.2 mg liraglutide should be considered as the starting dose in most patients with 
type 2 diabetes, with recommendations for titration up to 1.8 mg if target HbA1c concentrations are not reached. 
However, no study has been published in which patients who were insufficiently controlled on 1.2 mg liraglutide 
had a significant improvement in glucose control from an increased dose of 1.8 mg liraglutide. 
The superiority of liraglutide versus sitagliptin for blood glucose control and weight reduction was probably due 
to increased circulating concentrations of the GLP-1 agonist, leading to different pharmacological effects, as 
shown with exenatide.14 Even though Pratley and colleagues recorded superior treatment satisfaction with 1.8 mg 
liraglutide than with sitagliptin, the gastrointestinal tolerance profile is better with sitagliptin than with 
liraglutide, and one pill of sitagliptin daily might be judged as easier to administer than one subcutaneous 
injection of liraglutide daily. The increased cost of liraglutide should be compared with the benefit provided by 
improved glucose control and weight reduction. 
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Table: Main randomised trials assessing efficacy of DPP-4 inhibitors or GLP-1 receptor agonists in patients 
with type 2 diabetes who had inadequate glycaemic control on metformin 











DPP-4 inhibitors      
100 mg sitagliptin once daily      
Charbonnel et al (2006)8 464 24 7.96% -0.67% -0.70 
Scott et al (2008)9 94 18 7.70% -0.73% -0.40 
Nauck et al (2007)10 588 52 7.40% -0.67% -1.50 
Bergenstal et al (2009)4 166 26 8.50% -1.00% -0.90 
Pratley et al (2010)6 219 26 8.5% -0.90% -0.96 
50 mg vildagliptin twice daily      
Ferrannini et al (2009)12 1396 52 7.30% -0.44% -0.20 
5 mg saxagliptin once daily      
De Fronzo et al (2009)13 191 24 8.10% -0.68% -0.87 
GLP-1 agonists      
10 µg exenatide twice daily      
De Fronzo et al (2005)11 113 30 8.18% -0.78% -2.8 
Drucker et al (2008)3† 147 30 8.30% -1.50% -3.6 
Buse et al (2009)2‡ 231 26 8.20% -0.79% -2.87 
2 mg exenatide (longacting release) 
once weekly 
     
Drucker et al (2008)3§ 148 30 8.30% -1.90% -3.70 
Bergenstal et al (2009)4 160 26 8.50% -1.55% -2.70 
1·2 mg liraglutide once daily      
Nauck et al (2009)7 100 26 8.30% -1.10% -2.60 
Pratley et al (2010)6 221 26 8.4% -1.24% -2.86 
1·8 mg liraglutide once daily      
Nauck et al(2009)7 100 26 8.40% -1.00% -2.80 
Buse et al (2009)2‡ 233 26 8.20% -1.12% -3.24 
Pratley et al (2010)6 218 26 8.4% -1.50% -3.38 
*Result at end of follow-up (intention to treat, last observation carried forward) versus baseline. †34% of patients on metformin alone. ‡27% 
of patients on metformin alone. §38% of patients on metformin alone. 
 
Some important information is still unknown, but could help clinicians to choose the best incretin therapy to 
manage type 2 diabetes after failure with metformin. We do not know how the efficacy of GLP-1 receptor 
agonists versus DPP-4 inhibitors will vary long term during the progressive decline in β-cell function that is 
responsible for loss of glucose control, and the development and progression of chronic diabetic complications. 
Long-term safety also remains an open question. In our opinion, the range of type 2 diabetes is so heterogeneous 
that treatment probably needs to be tailored to individuals ratherthan strictly standardised.5 Such an approach 
would need to take into consideration all biological, clinical, and psychosocial characteristics of every patient. 
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